Aumolertinib
Drug for treatment of cancer
- 1 min read
- 2 chapters
Related on Lably
Through Therapy
Medical uses
In China, aumolertinib is approved for the treatment of people with EGFR T790M mutation—positive non-small-cell lung cancer who have progressed on or after other EGFR tyrosine kinase inhibitor therapy.
In the European Union, aumolertinib, as monotherapy, is indicated for the first-line treatment of adults with advanced non-small-cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations; and for the treatment of adults with advanced EGFR T790M mutation positive NSCLC.
Sign in to keep reading
One more chapter is free with a Lably account.
Society and culture
Legal status
In December 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Aumseqa, intended for the treatment of non-small cell lung cancer (NSCLC). The applicant for this medicinal product is SFL Pharmaceuticals Deutschland GmbH. Aumolertinib was authorized for medical use in the European Union in February 2026.
Names
Aumolertinib is the international nonproprietary name.
Aumolertinib is sold under the brand names Ameile and Aumseqa.